Vir Biotechnology appoints Sung Lee as Chief Financial Officer

Vir Biotechnology has appointed Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27.

The appointment follows the resignation of Howard Horn, who will leave the company after a brief transition period.

Lee is an experienced CFO who brings more than 20 years of finance leadership expertise in biopharmaceutical and technology businesses to Vir. He began his career in the tax advisory business at PwC, and later spent 14 years at Gilead Sciences, where he served in roles of increasing responsibility and scope, ultimately leading the company’s global financial planning and analysis, and investor relations functions. He has since served as CFO of Sangamo Therapeutics, Inc., and, most recently, served as CFO of MorphoSys AG. He received a Master of Business Taxation degree from the University of Southern California and a bachelor’s degree in Economics from the University of California, Irvine. 

Vir Biotechnology is a commercial-stage immunology company: with its pipeline including product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.